Biomarkers for early Parkinson's diagnosis
Part of Brain & nervous system clinical trials.
This study looks for new markers in the blood or other samples to help diagnose Parkinson's disease earlier. It compares people with Parkinson's, related conditions (like multiple system atrophy or progressive supranuclear palsy), and healthy volunteers to find differences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with clinically confirmed or probable Parkinson's disease, or a related condition like multiple system atrophy or progressive supranuclear palsy.
- Your Parkinson's symptoms are mild to moderate (Hoehn & Yahr stage 2.5 or less).
- You are able to consent to participate.
- You do not have secondary parkinsonism (caused by other factors like strokes or medications).
- You do not have severe dementia, Alzheimer's disease, or ALS.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special 7‑Tesla MRI brain scan to measure tiny chemical (metabolite) differences in specific deep brain areas. It compares newly diagnosed, early-stage Parkinson’s patients who are not on Parkinson medication with healthy volunteers.
This study looks for early biological signals in blood or other samples to help doctors quickly tell the difference between Parkinson's disease and similar conditions. Identifying these signals early could lead to better, faster diagnosis and treatment.
This study examines changes in alpha-synuclein, a protein linked to Parkinson's, to better understand how the disease progresses. It may help researchers learn more about Parkinson's and improve future care.
This study uses digital tools and brain markers to detect Parkinson's disease early. It includes healthy people, those with early Parkinson's, and those with REM sleep behavior disorder (a possible early sign).
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
This study is looking for proteins in blood and other body fluids that could help detect brain diseases like Parkinson's, Alzheimer's, and ALS early. It aims to improve diagnosis and future treatments.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.